1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (614) 293-7526
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma
Implications for clinical trials in this patient population
Article first published online: 4 APR 2002
DOI: 10.1002/cncr.0680
Copyright © 2002 American Cancer Society
Additional Information
How to Cite
Perkins, J. G., Flynn, J. M., Howard, R. S. and Byrd, J. C. (2002), Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer, 94: 2033–2039. doi: 10.1002/cncr.0680
Publication History
- Issue published online: 4 APR 2002
- Article first published online: 4 APR 2002
- Manuscript Accepted: 13 DEC 2001
- Manuscript Revised: 5 JUL 2001
- Manuscript Received: 28 DEC 2000
Funded by
- Chronic Lymphocytic Leukemia Research Consortium. Grant Number: P01 CA81534-02
- Sidney Kimmel Cancer Research Foundation
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , Infectious complications of chemotherapy in clinically aggressive mature B and T cell lymphomas, European Journal of Internal Medicine, 2012, 23, 3, 255
- 2, , , , , , , Risk Factors for Pneumocystis jirovecii Pneumonia in Patients With Lymphoproliferative Disorders, Clinical Lymphoma Myeloma and Leukemia, 2012, 12, 1, 66
- 3, , , Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?, Current Hematologic Malignancy Reports, 2010, 5, 1, 35
- 4, , , , Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide, Clinical Journal of Oncology Nursing, 2010, 14, 4, 491
- 5, , Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia, Clinical Lymphoma, Myeloma & Leukemia, 2010, 10, 5, 361
- 6, , Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options, Leukemia & Lymphoma, 2010, 51, 7, 1188
- 7
- 8, , , Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?, Blood, 2009, 114, 13, 2581
- 9, , , Emerging therapies for patients with advanced chronic lymphocytic leukaemia, Blood Reviews, 2009, 23, 5, 217
- 10
- 11, , , , , , , , , , , , , , , , , , , , Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway, Blood, 2009, 115, 13, 2619
- 12, , Rediscovering alemtuzumab: current and emerging therapeutic roles, British Journal of Haematology, 2009, 144, 6Direct Link:
- 13, , , , , , Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab, Annals of Hematology, 2008, 88, 2, 121
- 14
- 15, , Chemoimmunotherapy of chronic lymphocytic leukemia, Best Practice & Research Clinical Haematology, 2007, 20, 3, 479
- 16, , , , , , , , , , The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy, Leukemia & Lymphoma, 2007, 48, 10, 1931
- 17, , , , , , , , , , A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, Annals of Hematology, 2006, 85, 5, 301
- 18, Emerging Monoclonal Antibody Therapies for Multiple Sclerosis, The Neurologist, 2006, 12, 4, 171
- 19, , , , , , Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia, Cancer, 2006, 106, 10Direct Link:
- 20, , , , , Strategies in the Management of Alemtuzumab-Related Side Effects, Seminars in Oncology, 2006, 33, 29
- 21, , , , , , , , , , The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia, Cancer, 2006, 107, 5Direct Link:
- 22Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,
- 23, , Infections associated with purine analogs and monoclonal antibodies, Blood Reviews, 2005, 19, 5, 253
- 24, Monoclonal antibody therapy of chronic lymphocytic leukemia, Cancer Immunology, Immunotherapy, 2005, 55, 2, 188
- 25, , , , Spinal epidural abscess complicating chemotherapy in patients with leukemia, Neurosurgical FOCUS, 2005, 18, 1, 1
- 26, Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues, Drugs & Aging, 2005, 22, 12, 983
- 27, , , , , , , A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL), Leukemia & Lymphoma, 2004, 45, 11, 2269
- 28, , Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia, Seminars in Hematology, 2004, 41, 3, 234
- 29, , , , , , , , , , , , Efficacy and Safety of Fludarabine and Cyclophosphamide Combined Therapy in Patients with Refractory/Recurrent B-Cell Chronic Lymphocytic Leukaemia (B-CLL)—Polish Multicentre Study, Leukemia & Lymphoma, 2004, 45, 6, 1159
- 30, , , , , , , , Guidelines on the diagnosis and management of chronic lymphocytic leukaemia, British Journal of Haematology, 2004, 125, 3Direct Link:
- 31
- 32
- 33, , , , DAB389IL2 (ONTAK®) fusion protein therapy of chronic lymphocytic leukaemia, Expert Opinion on Biological Therapy, 2003, 3, 1, 179
- 34, Immunologic monitoring in chronic lymphocytic leukemia, Current Oncology Reports, 2003, 5, 5, 419
- 35, , , , , The Role for Intravenous Immunoglobulin in the Treatment of West Nile Virus Encephalitis, Clinical Infectious Diseases, 2003, 37, 6, e88